Unknown

Dataset Information

0

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis.


ABSTRACT:

Background

This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19).

Methods

Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to calculate the pooled estimates. The study protocol can be accessed at PROSPERO (CRD42023394173).

Results

The baricitinib group had a significantly lower mortality rate and proportion of patients who received mechanical ventilation than the control group (OR = 0.61, 0.57; P = .008, 0.02; 95% CI 0.42-0.88; 0.35-0.92; I2 = 71% and 86%, respectively). The length of hospital stay and rates of severe adverse events were not significantly different between the 2 groups.

Conclusion

Baricitinib reduces mortality and mechanical ventilation requirements in patients with severe COVID-19. Therefore, we developed a comprehensive understanding of the role of baricitinib in patients with severe COVID-19.

SUBMITTER: Song W 

PROVIDER: S-EPMC10695502 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis.

Song Wenxin W   Sun Shishen S   Feng Yilong Y   Liu Liujun L   Gao Tianqi T   Xian Shaoxiang S   Chen Jie J  

Medicine 20231201 48


<h4>Background</h4>This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19).<h4>Methods</h4>Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to ca  ...[more]

Similar Datasets

| S-EPMC10703388 | biostudies-literature
| S-EPMC9624173 | biostudies-literature
| S-EPMC7897363 | biostudies-literature
| S-EPMC9270852 | biostudies-literature
| S-EPMC10559905 | biostudies-literature
| S-EPMC8201261 | biostudies-literature
| S-EPMC7644182 | biostudies-literature
| S-EPMC8325414 | biostudies-literature
| S-EPMC8604568 | biostudies-literature